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ABSTRACT

Ibuprofen is known to plasticize several polymers used in the pharmaceutical field, and it
is considered challenging to achieve an immediate release by fused deposition modeling (FDM).
Therefore, this study aimed to print ibuprofen tablet with a focus on achieving immediate release.
Polyethylene oxide (Polyox WSR N80) was used as a main matrix to form the ibuprofen
filament due to its water-soluble property and manifesting suitable mechanical property even
with the high drug loading (40% w/w). Several release modifiers such as Kollidon VA64,
Kollidon 12PF, Kollicoat IR, Kollidon CL, and Mannitol were added separately to the
formulation to enhance the drug release rate. The effects of each release modifier on the drug
release rate and the mechanical property of the filaments were discussed. It was observed from
the results that adding soluble Kollidon grades such as Kollidon VA64 and Kollidon 12PF can
enhance the drug release rate. The tablet design with a high surface to mass ratio was also
beneficial to increase the drug release rate. However, the incorporation of the release modifiers
decreased the flexural modulus of the filament. Additionally, it was important to tailor the
printing parameters considering the filament’s property to acquire a good quality of printlets. In
this study, the tablet consisting of 30% ibuprofen, 20% Kollidon VA64 with the highest dose
(84mg) released 80% of the drug in approximately 90min. To further increase the release rate
and drug dose, other additives such as viscosity-increasing agent and reinforcing additive can be
explored. Therefore, this study can show the potential of fabricating ibuprofen tablets with
immediate release property using Polyox WSR N80 by fused deposition modeling.
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1. INTRODUCTION

Fused Deposition Modeling (FDM) is one of the methods of printing 3-dimensional
structures and it is well known for its cost-effective advantage compared to other methods. Over
the last few years, research on utilizing this technique for producing personalized drugs has been
growing in the pharmaceutical field, because FDM can be utilized to produce the drug with
customized release, flexible dose and a certain design.
FDM process is firstly done by feeding a thermoplastic filament from a large spool
(Figure 1). The filament is grabbed by the extruder gear and pushed down toward the hot end.
The nozzle is heated to melt the filament and moved in x, y, z directions according to a
predetermined design. The model is built up layer by layer as the material hardens immediately
after extrusion from the nozzle. In order to achieve good bonding between filaments which leads
to good quality, printing parameters such as printing temperature and deposition speed should be
carefully controlled.
Filaments for FDM can be fabricated by hot-melt extrusion (HME) which can be also
used to achieve the solid dispersion of the drug to increase the dissolution rate. To fabricate the
filament with high mechanical property, mostly polymers with a high molecular weight are
chosen as a carrier, which can in turn decrease the drug release. Therefore, an immediate release
is challenging to achieve from FDM. Until now, Kollidon VA64, Kollidon 12PF, and Eudragit
EPO have been reported to be used for immediate release in FDM 3D printing[1–3].
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Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) which is widely used to
reduce fever, pain, and inflammation. It is weakly acidic (pKa = 4.5)[4,5] and poorly soluble in
water (0.078μg/ml)[6]. It has been reported to plasticize several polymers including Ethyl
Cellulose, Eudragit EPO, Kollidon SR, Kollidon VA64 and polyethylene oxide[7–12].
Plasticization can alter the mechanical and thermal properties of polymers. The flexibility of the
polymer can be increased as the mobility of polymer chains is increased, which is translated to
lowered glass transition temperature. This can be helpful in the application where increased
flexibility or lower thermal processing for polymer is desired. However, for the filaments used in
3D printing, adequate flexibility is needed. Plasticization can help to achieve flexibility for
overly stiff materials, but it can also make filament too flexible and soft to print. Therefore, the
incorporation of ibuprofen which can act as a plasticizer can be a double-edged sword for
obtaining good filament for 3D printing. Also, ibuprofen is known to decompose over 180℃
[13,14], which imposes the thermal condition for hot-melt extrusion and fused deposition
modeling. Therefore, considering these possible challenges, this study aimed to print tablets
containing ibuprofen as a drug with a focus on achieving immediate release.

Figure 1. Diagram of FDM 3D Printer (Direct extruder)
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2. MATERIALS AND METHODS

2.1 Materials
Ibuprofen (IBU) was supplied from Spectrum Chemical Mfg. Corp (Gardena, CA).
Polyethylene oxide (Polyox WSR N10 molecular weight: 100k, Polyox WSR N80 molecular
weight: 200k) were donated by the Dow Chemical Company (Midland, MI). Eudragit EPO was
supplied from Evonik Industries AG (Essen, Germany). Kollidon VA64, Kollidon 12PF,
Kollidon CL, and Kollicoat IR were supplied from BASF (NJ, USA). Mannitol was supplied
from Alfa Aesar Chemicals (MA, USA). All other chemicals and reagents used in this study were
of analytical grade.

2.2 Methods
2.2.1 Formulation
Initially, Eudragit EPO, Kollidon VA64, Kollicoat IR, and Polyox WSR N80 (PEO N80)
were investigated for forming ibuprofen filament. Each polymer was loaded with different
concentrations (20, 30, 40 % w/w) of ibuprofen and examined.
After PEO N80 was chosen as a main matrix, to enhance the release, different release
modifiers such as Kollicoat IR, Kollidon VA64, Kollidon 12PF, Kollidon CL, and Mannitol were
added separately to the formulation. Firstly, fixing the drug loading to 20% w/w, 5% w/w of
Kollidon CL (crospovidone), 10% w/w of Kollidon VA64, Kollidon 12PF, Kollicoat IR were
incorporated. Among the release modifiers, Kollidon VA64 was added more due to its better
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performance than others. It was increased from 10% w/w to 30% w/w in the formulation with the
drug loading of 30% w/w or 40% w/w. 20% w/w of Mannitol was also examined with the drug
loading of 30% w/w. The composition of the formulations and the printability are summarized in
Table 1.

Table1. Formulation composition and printability
Formulation

F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
F13
F14

Ibu
(w/w, %)

PEO
N10
(w/w, %)

20
20
30
40
20
20
20
20
30
30
30
30
40
40

80

PEO
N80
(w/w, %)
80
70
60
75
70
70
70
50
60
50
40
50
40

Release modifier (w/w, %)
Kollidon
CL

Kollicoat
IR

Kollidon
12PF

Kollidon
VA64

Printability
Mannitol

5
10
10
10
20
10
20
30
10
20

o
o
o
o
o
x
o
o
o
o
o
x
o
o

*o denotes printable, x denotes not printable

2.2. Hot-melt extrusion
A co-rotating, twin-screw extruder with 11mm screw (Thermo Fisher Scientific, Waltham,
MA, USA) was used in this study. Physical mixtures were manually fed and extruded at 60-70℃
with a standard screw configuration at a screw speed of 50 rpm. When extruded, the observed
torque and pressure bar was 17-36% and 45-62bar, respectively. A round die with a diameter of
0.75mm was used to obtain the filaments with the optimal range of diameter (1.5mm~1.75mm)
for the 3D printer. Extruded filaments were kept in polybags with silica gel until they are loaded
to the 3D printer.
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2.3. Design and printing of tablets
Tablets were printed using a commercial FDM 3D printer (Prusa i3 MK3 3D desktop
printer, Prusa Research, Prague, Czech Republic) with a 0.4mm nozzle. For designing the tablet,
the Tinkercad software (Autodesk Tinkercad, Autodesk Inc., CA, USA) was used to make donut
and disk shape. Additionally, a flower shape was created hoping to arouse a patient-friendly
feeling. Printing parameters were adjusted using the Ultimaker software (Ultimaker Cura version
15.04; Ultimaker, Geldermalsen, Netherlands) as follows; printing temperature: 180℃, bed
temperature: 25℃, print speed: 10mm/s, layer height: 0.2mm, flow: 90%, infill: 100%. The
acceleration control option was enabled and set to 500mm/s2 .

2.4. Differential scanning calorimetry
A differential scanning calorimetry (DSC) (TA Instruments, New Castle, DE, USA) was
used to study the crystallinity and thermostability of the drug. Approximately 5–8 mg of pure
ibuprofen, PEO N80, and extrudates were heated from 25 to 200°C at a rate of 20°C/min.
Nitrogen was used as a purge gas at a flow rate of 50 mL/min.

2.5. Three-point bend test
A three-point bend test was conducted to compare the mechanical properties (flexural
modulus and fracture strength) of the filaments. The test was carried out by the TA-XT2 analyzer
(Texture Technologies, Hamilton, MA, USA) and the TA-95N probe set. Filaments were cut into
5cm in length and placed on the supports with a 25mm gap. The Exponent software (Texture
Technologies Corp. and Stable Micro Systems, Ltd., Hamilton, MA, USA) was used to obtain
the data set of force and distance for each sample. The TA settings were adjusted as follows; Pre-
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test speed: 0.5mm/s, test speed: 0.02mm/s, post-test speed: 10mm/s, distance: 4.5mm. The test
was repeated six times for each sample.
The force and distance data were put into the below equations which are commonly used
to calculate stress and strain in three-point bending and the resultant stress-strain curves were
drawn by the MATLAB software (The Mathworks Inc., Natick, MA).

For a specimen with a circular cross-section,

Flexural stress (Mpa): σ =

𝐹𝐿

⋯ (Eq.1)

𝜋𝑟 3

where,
F: Applied force [N]
L: Distance between the two supports [mm]
r: Radius of the test rod [mm]

Relative strain (%): ε =

6𝐷𝑑
𝐿2

⋯ (Eq.2)

×100

where,
D: Maximum deflection of the center of the rod [mm]
d: Diameter of the test rod [mm]
L: Distance between the two supports [mm]
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2.6. In vitro dissolution study
The dissolution study was performed in 900ml of pH 7.2 phosphate buffer using USP
type 1 dissolution apparatus (Hanson SR8-plus; Hanson Research, Chatsworth, CA, USA). The
temperature of the medium was maintained at 37 ± 0.5°C and the rotation speed of the basket
was set at 50rpm. Each experiment was done in triplicate. Samples were withdrawn at 5, 15, 30,
45, 60, 90, 120, 150, and 180 min and analyzed using a UV-Vis spectrophotometer at the
wavelength of 221 nm.

2.7 Drug content study
In order to assess whether the drug degradation occurred during 3D printing, drug content
inside HME filaments (before printing) was measured and compared to that of 3D-printed tablets.
For the drug content study of HME filaments, three filament samples were randomly taken
and accurately weighed to 30mg. Each sample was placed in a 250ml volumetric flask
containing pH 7.2 phosphate buffer and the sonication lasted at least 30 minutes or extended
more if needed to ensure complete dissolution. The samples were then analyzed using UV-Vis
spectrophotometer at the wavelength of 221nm. For the drug content study of 3D-printed tablets,
samples were dissolved 15 minutes more with 200rpm after the last time point during the in vitro
dissolution study to ensure complete dissolution. Samples were then withdrawn and analyzed
using UV-Vis spectrometer at the wavelength of 221nm. % Drug content was determined by
dividing the experimental value by the theoretical value of the drug amount inside the filament or
tablet. Absolute drug content was also determined which refers to the real mass of the drug inside
the tablet.
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3. RESULTS AND DISCUSSION

3.1 Formulation
3.1.1 Investigation of main matrix for ibuprofen
Initially, Eudragit EPO, Kollidon VA64, Kollicoat IR, and PEO N80 were examined for
their use as a main matrix for ibuprofen. Each polymer was loaded with different concentrations
(20, 30, 40 % w/w) of ibuprofen and melt-extruded. The suitability of the polymer as a main
matrix was decided by the following conditions; (1) whether 20% w/w or more of ibuprofen can
be loaded exhibiting suitable mechanical property for 3D printing, (2) whether the thermal
processes (Hot-melt extrusion and 3D printing) can be done without the degradation of ibuprofen.
Eudragit EPO was screened out mainly due to its poor water solubility in pH 7.2. USP
recommends testing the dissolution behavior of ibuprofen in pH 7.2 which can be due to
inadequate dissolution of the drug in an acidic environment[6], and Eudragit EPO is not soluble
over pH 5 as a pH-dependent polymer. Therefore, Eudragit EPO was not investigated further.
However, here reports the property of the filaments based on Eudragit EPO. With 20% w/w of
ibuprofen, brittle filament was obtained. With 30% w/w of the drug, the filament was excessively
flexible and sticky. This observation indicates that ibuprofen acted as a plasticizer for the
polymer. (The observations are based on the extrusion temperature of 90℃.)
With 20% w/w of ibuprofen, filament based on Kollidon VA64 was highly sticky in the
solid-state. With the 40% w/w of ibuprofen, the filament couldn`t be formed as it came out as
melted from the extruder. (The observations are based on the extrusion temperature of 140℃.)
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Above all, due to excessive stickiness which can harm the printer parts making the removing
process hard, it was decided not to use Kollidon VA64 as a main matrix and not more than 40%
w/w.
Kollicoat IR was investigated for its use as a main matrix as it is widely used as an
immediate release film former. For Kollicoat IR, with 20% w/w of ibuprofen, extruded filaments
showed recrystallization of the drug on the surface (Figure S1, Appendix). This is not desirable
due to potential drug loss during processing. With 10% w/w of drug loading, recrystallization
didn`t occur and printing was possible, however, it was not laminated well producing the
separation of the layers during building at 180℃ of printing temperature, and at least 150-160℃
was required for successful hot-melt extrusion. As this study desired drug loading to be at least
20% w/w, and due to the potential risk of thermal decomposition of ibuprofen owing to the
likelihood of increasing printing temperature more than 180℃, Kollicoat IR was screened out.
Finally, polyethylene oxide was examined. It is sometimes used as a controlled-release
matrix due to its water-swelling ability. However, as it is basically water-soluble, it has the
potential to achieve fast release with the addition of release modifiers. It has different swelling
capacity depending on the molecular weight. Therefore, the two lowest grades (PEO N10 and
PEO N80) were used since the release would be not much retarded due to their lower molecular
weight. Using the polymer as a main matrix, filaments with suitable mechanical property could
be obtained even with 40% w/w of the drug loading.

3.1.2 Addition of release modifiers
After polyethylene oxide was chosen as a main polymer, different release modifiers were
added to enhance the drug release rate. Fixing the drug loading to 20% w/w, 5% w/w of Kollidon
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CL (crospovidone), 10% w/w of Kollidon VA64, Kollidon 12PF, and Kollicoat IR were added
separately to the formulation and were examined for their effect on the drug release rate and
mechanical property of the filament. Kollidon CL was tried in the formulation as it is widely
used as a super-disintegrant. Kollidon VA64, Kollidon 12PF, and Kollicoat IR were added as
they are readily soluble in water. It was revealed from the dissolution study (section 3.6) that
adding Kollidon VA64 and Kollidon 12PF is beneficial to increase the drug release rate.
However, the three-point bend test (section 3.5) indicated that the filament added with Kollidon
VA64 has slightly better mechanical property (higher flexural modulus) than the one added with
Kollidon 12PF. Therefore, the content of Kollidon VA64 was increased more (10% w/w ~ 30%
w/w) in the formulation with the drug loading of 30% w/w or 40% w/w. Also, 20% w/w of
mannitol was added into the formulation with the drug loading of 30% w/w. Mannitol was
examined as it has been reported to enhance the drug release rate in swellable polymer matrix
functioning as a channeling agent[15]

3.2 Hot-melt extrusion
The extrusion temperature was set at 60-70℃ for all formulations. Filaments underwent
die swell at this temperature, therefore, a round die with the small diameter (0.75mm) was used
to obtain the filaments with the satisfying thickness (1.5~1.75mm) for 3D printing. Overall, the
obtained filament diameter was 1.6mm ± 0.08mm.
Achieving homogeneous thickness of filament is important in 3D printing as it is related
to the quality of printlets. More homogeneous the diameter of the filaments, the amount of
extrudates flowing from the printer nozzle per time can be more similar, and this can affect the
quality of printlets.
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For the filaments based on PEO N80, in a semi-solid state, they were easily deformed by
a small force compared to the filaments based on the other polymers that were examined as a
main matrix. Due to this reason, conveyor belt was not used as it stretched the filament a lot even
at a very low speed, and it was desirable not to touch the filament at all during the extrusion.
However, while getting the filament, it was inevitable to touch it when it tried to make a curl.
These are thought to have influenced the homogeneity of the thickness of the filament.
Also, a consistent feeding rate was important for obtaining a homogeneous thickness.
When the feeding rate was suddenly changed, there was a fluctuation in filament thickness, and
when the feeding was stopped, the thickness was decreased. Though the feeding rate was kept
consistent as best as possible, the feeding was done manually, therefore, it could have impacted
the homogeneity of the thickness of the filaments.

3.3. Design and printing of tablets

Figure 2. Design of the tablets

Tablets in this study had the three designs described as donut, flower, and disk shape
(Figure 2). The disk was the simple cylinder shape, and the donut was made from the same
cylinder creating the hole at the center. Flower had a slightly more complicated design with five
petals but had the same size of the hole at the center as a donut. The center holes in the donut and
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flower were made hoping to increase the release by increasing the specific surface area. The
dissolution profile shown in Figure 8a confirms that this approach works out. For an accurate
comparison, tablets were adjusted to have a similar total weight (Disk shape was built at 1.4mm
in height rather than 2.0mm to achieve a similar total weight as flower and donut shape). The
design with the hole at the center was better for drug release as this design facilitates more
contact with the release medium.
It was initially expected that printing would be possible at low temperature as the melting
point of ibuprofen (79℃) and PEO N80 (73℃) is low. However, the filaments didn`t come out
from the nozzle up to 175℃. From 180℃, the filaments began to flow out from the nozzle which
means at this temperature, enough heat could be provided to melt the filament quickly inside the
nozzle. Although the printing temperature is close to the decomposition temperature of ibuprofen
(180℃~)[13,14], it was confirmed by the drug content study that no significant drug degradation
occurred (Table 2). It is thought that fast heating and short residence time of the filaments inside
the printer allowed negligible or no degradation. For the print bed temperature, it was set at 25℃,
not following the default setting for PLA (60℃). As polyethylene oxide and ibuprofen showed
high stickiness at molten state, it was decided to set the bed temperature far lower than the
melting point of PEO N80 (73℃) and ibuprofen (79℃) to prevent printlets from sticking too
much on the bed.
Table 2. Drug Content of HME filament and 3D-printed tablet from F3, F11.
Formulation

Drug content (Mean±SD)
HME Filament (%)
3D-Printed Tablet (%)

F3 ibu 30%
98.9±3.7
98.7±0.8
F11 ibu 30% + VA64 20%
101.1± 1.3
102.4± 0.6
*It can be known that drug degradation didn`t occur after 3D printing. F3 was studied for drug

content representing the formulations consist of ibuprofen and polyethylene oxide. F11
represents the formulations consist of ibuprofen, polyethylene oxide and Kollidon VA64.
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Printing speed was set at 10mm/s for steady deposition of the material. As shown in
Figure 3a, the tablet quality was decreased with an increase in speed. Printing speed defined in
the Ultimaker is the speed at which the print head moves while printing. An increase in speed can
introduce more turbulence and vibration by the fast movement of the printer nozzle. It can also
lessen the time for one layer to be cooled before the other layer is built on. As observed in the
hot-melt extrusion, the filaments based on polyethylene oxide were easily deformed with tiny
force in a semi-solid state, which means they are susceptible to vibration. Therefore to ensure
enough cooling and stable building, the print speed was set low. Acceleration control was also
enabled for the same reason.
The flow value was also decreased to 90% from the default value of 100%. It is the
amount of material that is extruded over a specific amount of time through the nozzle. The
mechanism of controlling the flow in the printer is by changing the rotating speed of extruder
gear that pushes the filament out. Initially, it was set more than 100% to compensate for the
smaller diameter (around 1.6mm) of the filaments than the standard diameter (1.75mm) because
a smaller diameter can lead to less flow from the nozzle. However, an increase in the flow
yielded horizontal expansion of the tablet due to the deposition of an excessive amount of the
material (Figure 3b). Even at the decreased flow of 90%, it didn`t show under-extrusion which
can indicate filaments in this study have low melt viscosity which can be mainly due to using
PEO N80 and the plasticizing effect of ibuprofen. As there was no difference in the appearance
of the tablet with 100% flow and the filaments in this study were highly flexible, it was
determined to keep the value at 90% to reduce the risk of tangling inside the printer by pushing
the filament gently with less speed even though it would have a small impact.

13

Layer height which describes the thickness of one layer was set at 0.2mm as tablets were
made well at this value (Figure 3c). When the layer height of 0.5mm was used, printing time
was decreased; however, the tablet became coarse as fewer layers were used to build the tablet.

3a.

5

10

15
20
30
Printing speed (mm/sec)

90

100
110
Flow (%)

40

60

3b.

120

3c.

0.15

0.2

0.3
0.4
Layer height (mm)

0.5

0.6

Figure 3. Effect of printing parameters on print quality (a) Effect of printing speed on print
quality. (b) Effect of flow on print quality. (c) Effect of layer height on print quality. All of the
tablets shown in Figure 3 are based on F3 (ibu-30%)

Overall, the printed tablets had consistent deformation throughout the building process.
As shown in Figure 4, one side of the tablets underwent more shrinkage than the other side. This
may due to the less cooling effect on one side. In the case of the printer used in this study (Prusa
MK3s i3), the cooling fan that is used to solidify the printlets is located in front of the printer (to
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be exact, in front of the nozzle). The side with less deformation was toward the cooler and the
opposite side was away from the cooler. The side toward the cooler might have been solidified
well; however, the opposite side that is away from the cooler may have gotten a lower cooling
effect thus having more time to be influenced by heat resulting in more contraction and
deformation. The effect of less cooling is thought to be severe on the filament based on
polyethylene oxide as PLA didn`t show the issue. If the fan power is increased more than
maximum value by changing to a strong motor or if one more fan is installed behind the nozzle,
this issue might be resolved.

4a.

a

b a

4b.
a

b

b a

b

Figure 4. Side view of the tablets (a) Side view of F11 (ibu-30%, VA64-20%) tablet built into
4mm-donut shape (ibu-30%, VA64-20%) (b) Side view of F13 (ibu-40%, VA64-10%) tablet
built into 2mm-flower shape. Side a is away from the cooler, and side b is toward the cooler. All
of the tablets had a similar deformation at the side a.

Tablets were printed with 100% infill density, which means the inside of the tablet was
fully filled because tablets were built more deformed at lower infill density (Figure S2,
Appendix). This can be due to the deformation problem mentioned above. Also, as the filaments
in this study were easily deformable with a small force in a semi-solid state, the stable building
could have been harder to be achieved under the condition of less support and high porosity. To
assure better building and appearance, all tablets were printed with 100% infill density in this
study.
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Also, there were differences in the capability of building tablets among the formulations.
The formulations only consist of ibuprofen and polyethylene oxide produced poor print quality if
built more than 3mm in height (Figure S3, Appendix). Therefore, all of the formulations were
printed at 2mm in height for the comparison of the dissolution profile. However, the
formulations added with mannitol, Kollidon VA64 and Kollidon 12PF overall showed better
building process. This was reflected in the better appearance of flower-shaped tablets which has
slightly more complicated shape than donut in these formulations. It is thought that increased
crystallinity by the addition of those ingredients served as an aid for better building. In theory,
the glass transition temperature of VA64 (101℃), 12PF (90℃), and the melting point of
mannitol (165℃) is higher than the processing temperature of hot-melt extrusion used in this
study (60℃), therefore, there could be remaining crystallinity inside the matrix. Among the
formulations, F11 (ibu-30%, VA64-20%) was built well to 4mm in height (Figure 5). It is
considered that appropriate melt viscosity and stickiness achieved in this formulation enabled
better building. However, F14 (ibu-40%, VA64-20%) was not built to 4mm under the same
printing parameters. It showed high flowability from the nozzle and increased stickiness of the
tablet compared to F11 which can be due to the increased content of ibuprofen. It is also
noticeable that F1 (ibu-20%, PEO N10) showed higher flowability from the nozzle than F2 (ibu20%, PEO N80) under the same processing parameter, which can be due to the lower molecular
weight of PEO N10 (100,000da) than that of PEO N80 (200,000da). For this formulation, the
flower shape was built poorly (the distinction between the petals was not obvious, thus looking
like a donut) because of the overflow of the material.
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5a.

5b.

Figure 5. Image of 4mm height tablets (a) Image of 4mm-flower-shaped tablet, (b) Image of
4mm-donut-shaped tablet. Both tablets were made from F11 (ibu-30%, VA64-20%)

3.4. Differential scanning calorimetry
Figure 6 shows the DSC thermograms of pure ibuprofen, PEO N80 and the extrudates. It
can be seen that the ibuprofen melting peak (79℃) disappeared in the thermograms of extrudates.
This indicates ibuprofen was molecularly dispersed in the polymer matrices and became
amorphous, which can enhance the dissolution rate of the ibuprofen in the formulation.

Figure 6. DSC thermograms of pure ibuprofen, PEO N80, and HME filaments. DSC
thermogram of F3 (30% ibu) after 3D printing is also shown.
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3.5 Three-point bend test
In FDM 3D printing, filament should have a suitable mechanical property to be fed inside
the printer. It should have a certain amount of bending stiffness and not be brittle. If the filament
is too stiff, it will not permit winding onto spools[16], however, if the filament is too flexible, it
can bend by the pushing force of the extruder gear rather than straightly move forward, thus not
being expelled from the nozzle. Also, it should be strong enough to withstand the force exerted
by the extruder gear without breaking.
The mechanical properties related to the above can be evaluated by a three-point bend
test. One mechanical parameter that can be known is the flexural modulus (bending modulus). It
describes the material’s resistance to bending and can be obtained from the slope of the initial
linear region of the stress-strain curve. The lower the flexural modulus, it means the material is
easier to be bent under the given force. Other parameter that can be known is the flexural
strength (fracture strength). It represents the highest stress experienced within the material at its
moment of rupture and can be easily noticed from the peak of the curve.
Overall, the filaments in this study were not brittle and highly flexible compared to
commercial PLA which can be confirmed by a very low value of flexural modulus compared to
that of PLA (Table 3).
Figure 7 presents the stress-strain curves of all formulations. It is noticeable that the
filaments added with the release modifiers have a lower initial slope (which means lower flexural
modulus) than the filaments only consist of ibuprofen and PEO N80. Also, as the content of
Kollidon VA64 increased, the flexural modulus decreased, which means the filaments became
more flexible with the increasing content of VA64 (Figure 7b, 7c). The possible reason could be
that as the release modifiers in this study had either branched structure or relatively lower
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molecular weight than PEO N80 which mainly forms the matrix, they could have reduced the
interaction between polyethylene oxide chains, thus increasing the mobility of the chains
compared to the case where polyethylene oxide exists fully.
Compared to the formulation added with Kollidon 12PF (F7), the one added with
Kollidon VA64 (F8) exhibits slightly better bending stiffness which is translated to a higher
flexural modulus (Figure 7a). This may due to the relatively higher molecular weight of
Kollidon VA64 (45000-70000da) than that of Kollidon 12PF (2500da).
Even though the filaments added with 20% of VA64 (F11, F14) were highly flexible by
feel which can be also confirmed by a considerably low value of flexural modulus, it could be
fed and printed by the printer. The filament containing 30% of VA64 couldn`t be printed out
which may due to excess flexibility. However, the filament was obtained relatively thin during
hot-melt extrusion compared to the other formulations, not exceeding 1.5mm in most regions.
This is considered to be the main reason for not being printed by the printer.
Although the filaments with Kollicoat IR (F6) and Kollidon 12PF (F7) had a similar
flexural modulus, F6 couldn`t be printed out due to brittleness. It was broken by the extruder
gear during printing. This can be confirmed by the rapid decline in stress in the F6 curve (Figure
7a). Whereas F7 withstood the stress of 5.812Mpa, F6 started to break under the same stress.
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Table 3. Flexural modulus of commercial PLA and filaments in this study
No.

Formulation

F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
F13
F14

PLA (reference)
ibu 20%
ibu 30%
ibu 40%
ibu 20% + Kollidon CL 5%
ibu 20% + Kollicoat IR 10%
ibu 20% + Kollidon 12PF 10%
ibu 20% + Kollidon VA64 10%
ibu 30% + Mannitol 20%
ibu 30% + Kollidon VA64 10%
ibu 30% + Kollidon VA64 20%
ibu 30% + Kollidon VA64 30%
ibu 40% + Kollidon VA64 10%
ibu 40% + Kollidon VA64 20%

7a.
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Flexural Modulus
[MPa]
3265
439.1
332.9
326
267.7
210.9
208.5
274.8
229.2
178.8
84.7
42.05
221.6
70.88

7b.

7c.

Figure 7. Stress-strain curves of the filaments (a) Stress-strain curves of the filaments added
with different release modifiers are shown. The change in curve with increasing drug content
(20-40% w/w) also can be observed. (b) Stress-strain curves of the filaments added with different
percentages of Kollidon VA64 and Mannitol are shown. (Drug loading in here is 30%). (c)
Stress-strain curves of the filaments added with different percentages of Kollidon VA64 are
shown. (Drug loading in here is 40%)
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3.6 In vitro dissolution study
The dissolution study of ibuprofen was performed in 900mL of pH 7.2 Phosphate buffer
as recommended by USP. Although it is also recommended to use USP apparatus 2 (paddle
method) at 50rpm, since the tablets stuck to the bottom of the vessel or floated when the tablet
weight was low, which can bring about large variation in dissolution behavior[17], USP
apparatus 1 (basket method) was utilized instead, to ensure full exposure of the tablet surface.
For the dissolution study, the donut-shaped tablet with 2mm height was utilized to assess
and compare the dissolution profile of each formulation. Approximately 30mg, 40-50mg, 60mg
of ibuprofen was inside the tablet when the drug load was 20%, 30%, and 40% w/w, respectively
(Table 4). Overall, the dissolution behavior of the tablets was initial swelling followed by
erosion, which can be due to using polyethylene oxide as a main matrix.
Figure 8b compares the dissolution rate of the tablets incorporated with different
percentages (20%, 30%, 40% w/w) of ibuprofen. Although the dissolution rate of 30% w/w drug
load and 40% w/w drug load is not much different, it can be seen that the dissolution rate
decreases with increasing drug load. According to Figure 8b, 80% drug release was achieved
after two hours in both F3 (30% drug load) and F4 (40% drug load). Additionally, the figure
shows the release profile of the tablet based on PEO N10 (F1). It was initially expected that the
tablets based on PEO N10 (100,000da) would have much faster drug release than the ones based
on PEO N80 (200,000da) due to lower molecular weight. However, there was not much
difference in the drug release rate between PEO N10 and PEO N80.
Figure 8c compares the effect of different release modifiers on the drug release rate. The
formulation added with Kollicoat IR couldn`t be shown in this figure as it was not printable. The
data indicates that adding 10% w/w of Kollidon 12PF and Kollidon VA64 is beneficial to
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increase the drug release rate. It was initially expected that 5% w/w of Kollidon CL (superdisintegrant) would be beneficial due to its fast water-wicking ability, however, it didn`t improve
the release. The reason for this could be that 5% w/w was not enough to make it function as a
super-disintegrant as relatively high content of polyethylene oxide was liquefied and could have
sealed the disintegrant particles during hot-melt extrusion[18]. Although 20% w/w of Mannitol
was added to increase the release rate as it has been reported as a channeling agent[15], the
release was not improved.
As the formulation with Kollidon VA64 had slightly better stiffness than Kollidon 12PF
according to the three-point bend test, it was determined to increase the content of Kollidon
VA64 in the formulation and further evaluate the dissolution behavior. The concentration of
ibuprofen was fixed to 30% or 40% w/w this time. As shown in Figure 8d, 80% drug release
was achieved within 75min and within 60min in F10 (ibu-30%, VA64-10%) and in F11 (ibu30%, VA64-20%), respectively. This indicates that the drug release rate can be increased with
the increasing content of VA64.
As F11 (ibu-30%, VA64-20%) could be built more than 2mm in height, it was more built
into 4mm in height hoping to increase the drug dose and examined for the dissolution behavior.
Along with the donut shape, the flower shape was also tested for the dissolution. Figure 8e
shows the dissolution profile of the tablets. The amount of drug in the 4mm-donut-shaped tablet
and 4mm-flower-shaped tablet was approximately 84mg and 72mg, respectively (Table 4). From
the figure, it can be seen that 4mm height tablets released slower than 2mm height tablets as
expected due to large increase in total mass. It is also shown that 80% drug release was achieved
at about 90min for donut shape (4mm) and within 75min for flower shape (4mm). The possible
reason for flower shape having faster release than donut shape could be less drug content inside
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the tablet. Also, it is possible that the segments between the petals of the flower-shaped tablet
were worn out faster by erosion as they are relatively thin, thereby making the tablet
disintegrated and achieving the faster release.
The tablet with the highest dose (84mg) in this study released 80% of the drug at about
90min. Compared to the dissolution criteria of immediate release ibuprofen tablet, which is NLT
80% of drug release within 60min in pH 7.2 buffer according to USP, it is still slow. However,
the addition of other additives can be investigated to increase the release rate and drug dose.
Some viscosity-increasing agent can be explored for formulation 14 (ibu-40%, VA64-20%)
which had the problem of building into 4mm in height due to low melt viscosity, in order to
increase the drug dose. A reinforcing additive can be explored to enhance the mechanical
property for VA64-30% filament in order to increase the drug release rate.

Table 4. Tablet weight and drug content of the printed tablets (Mean ± SD)
Formulation
F1
F2
F3

20% ibu + 80% PEO N10
20% ibu + 80% PEO N80
30% ibu

F4
F5
F6
F7
F8
F9
F10
F11

40% ibu
20% ibu + 5% CL
20% ibu + 10% KIR
20% ibu + 10% 12PF
20% ibu + 10% VA64
30% ibu + 20% Mannitol
30% ibu + 10% VA64
30% ibu + 20% VA64

F12
F13
F14

30% ibu + 30% VA64
40% ibu + 10% VA64
40% ibu + 20% VA64

Shape (height)

Tablet weight
(mg)

Drug content (%)

Absolute drug
content (mg)

Donut (2mm)
Donut (2mm)
Disk (1.4mm)
Donut (2mm)
Flower (2mm)
Donut (2mm)
Donut (2mm)
Donut (2mm)
Donut (2mm)
Donut (2mm)
Donut (2mm)
Donut (2mm)
Flower (2mm)
Donut (4mm)
Flower (4mm)
Donut (2mm)
Donut (2mm)

148.9±5.8
178.2±3.0
155.9±7.9
169.6±2.9
154.5±1.9
162.0±3.8
143.6±3.0
143.9±2.9
135.7±0.6
178.7±3.9
160.7±4.9
134.8±0.4
124.8±0.1
270.5±1.0
235.4±0.7
160.8±4.2
145.7±3.7

99.3±1.6
95.0±2.8
97.5±0.2
98.7±0.8
95.0±0.9
101.7±5.8
97.1±2.0
104.5±1.5
100.3±0.8
99.2±1.1
101.3±0.3
102.4±0.6
94.2±2.2
103.5±0.9
101.8±4.2
100.67±0.5
99.6±2.6

29.6±0.5
33.9±1.0
45.6±0.1
50.2±0.4
44.0±0.4
65.9±3.8
27.9±0.6
30.1±0.4
27.2±0.2
53.2±0.6
48.8±0.1
41.4±0.2
35.3±0.8
84.0±0.7
71.9±3.0
64.8±0.3
58.0±1.5

* Absolute drug content refers to real mass of the drug inside the tablet.
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8a.

8b.

8c.

8d.

8e.

Figure 8. Release profiles of the printed tablets (a) Comparison of the release profiles of the
different shapes (disk, flower, donut) with similar total weight. Tablets are based on F3 (ibu-30%)
(b) Release profiles of the tablets with increasing content of ibuprofen. Release profile of the
tablets based on PEO N10 is also shown. (c) Effect of the release modifiers on the drug release
rate. (d) Release profiles of the tablets with increasing content of VA64. The effect of mannitol is
also shown. (e) Release profiles of 4mm-donut-shaped tablet and 4mm-flower-shaped tablet.
Release profiles of the tablets with 2mm height are also shown for comparison.
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4. CONCLUSION

This study aimed to fabricate ibuprofen tablets with a focus on achieving immediate
release. Considering the plasticization effect of ibuprofen, several polymers that are known for
immediate release property were tried as a main matrix for ibuprofen filament. However,
polyethylene oxide (Polyox WSR N80) was chosen as a base polymer to form the filament.
Though the polymer can release the drug slower due to initial swelling compared to other known
immediate release polymers, it was used as a main matrix for its water-soluble property and as it
could contain high content (~40% w/w) of ibuprofen exhibiting suitable mechanical property for
printing. In addition, thermal processes (Hot-melt extrusion and 3D printing) could be done
without thermal decomposition of ibuprofen with this polymer. With PEO N80 as a base, several
release modifiers such as Kollidon VA64, Kollidon 12PF, Kollicoat IR, Kollidon CL, and
Mannitol were incorporated in the formulation to increase the drug release rate. It was observed
from the results that adding Kollidon VA64 and Kollidon 12PF can enhance the drug release rate.
The design of the shape with high surface to mass ratio was also proved to be beneficial from the
study. However, the incorporation of the investigated release modifiers to the polyethylene oxide
matrix decreased the flexural modulus of the filament which can be due to lower molecular
weight of the chosen ingredients relative to that of polyethylene oxide.
During 3D printing, it was important to carefully tailor the printing parameters
considering the filament’s property to acquire dimensional accuracy and good appearance of the
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printlets. This indicates contemplation on the 3D printing process for each unique filament is
necessary to achieve a high quality of printlets. The quality of the tablets in this case is expected
to be enhanced more with the improvement in the aforementioned problems met during the study
(deformation from less cooling, inhomogeneous filament diameter). Other additives such as
viscosity-increasing agent or reinforcing additive can be explored to further increase the drug
release rate and drug dose by increasing the content of Kollidon VA64 and ibuprofen in the
formulation. Therefore, this study can show the potential of fabricating ibuprofen tablets with
immediate release property using Polyox WSR N80 by fused deposition modeling.
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S1.

Figure S1. Image of the filament (Kollicoat IR-80%, ibuprofen-20%)
It can be seen that recrystallization of ibuprofen occurred on the filament surface.

S2a.

S2b.

Figure S2. Image of the tablet with 40% infill made from (a) F7 (ibu-20%, 12PF-10%) (b) F13
(ibu-40%, VA64-10%). All of the tablets were deformed regardless of the formulation with a low
percentage of infill.

S3a.

S3b.

S3c.

Figure S3. Image of the tablet built into 4mm in height made from (a) F3 (ibu-30%) (b) F4 (ibu40%) (c) F11 (ibu-30%, VA64-20%). Formulations only based on ibuprofen and PEO N80 were
deformed as shown when built more than 3mm in height, whereas F11 which was added with 20%
of VA64 could be built stably to 4mm in height.
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